---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-134656"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:13:53.463841+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Eli Lilly to acquire Centessa for $38/share plus up to $9 in CVRs

## Summary
- Centessa shareholders receive $38.00 per share cash plus CVRs worth up to $9.00 per share on milestone achievement.
- CVR milestones: $2 for first US NDA of ORX750/ORX142 by Dec 31, 2029; $5 for IH approval within 5 yrs; $2 for NT2 approval within 5 yrs.
- Supporting shareholders owning ~20% of shares agreed to vote in favor of the scheme.
- Transaction expected to close by Sept 30, 2026, extendable to March 31, 2027 for HSR clearance.
- Termination fee of ~$63M payable by Centessa under certain circumstances.

## SEC filing metadata
- accession: 0001193125-26-134656
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000119312526134656/0001193125-26-134656-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000119312526134656/d145970d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-134656
- JSON: https://secwatch.observer/filing/0001193125-26-134656.json
- Plain text: https://secwatch.observer/filing/0001193125-26-134656.txt

## Key facts
- Material Agreements
  Centessa Pharmaceuticals plc entered into Transaction Agreement with Eli Lilly and Company and LDH XV Corporation (effective 2026-03-31).
  - Action: entry
  - Agreement: merger
  - Counterparty: Eli Lilly and Company and LDH XV Corporation
  - Effective: 2026-03-31
  source text: On March 31, 2026, Centessa Pharmaceuticals plc, a public limited company registered in England and Wales (the “Company”), entered into a Transaction Agreement (the “Transaction Agreement”) with Eli Lilly and Company, an Indiana corporation (“Parent”), and LDH XV Corporation, a Delaware corporation and direct wholly owned subsidiary of Parent (“Purchaser”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847903/000119312526134656/0001193125-26-134656-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.